Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion." ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

Constellation Energy rises sharply as Meta Platforms signs an agreement to buy power generation of a Constellation nuclear ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to ...

Constellation Energy (CEG) has inked a 20-year deal to provide tech giant Meta Platforms (META) with power from its clean ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Merck has held talks over a more than $3bn acquisition of Swiss biotechnology group MoonLake ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times ...